NEW YORK (TheStreet) -- RATINGS CHANGES

Halozyme Therapeutics (HALO) - Get Report was upgraded at UBS to buy from neutral, UBS said. Driven on pipeline potential and undervalued valuation, UBS said. Twelve-month price target is $16.

Hewlett-Packard (HPQ) - Get Report was upgraded at Goldman Sachs to neutral from sell. Management has executed far more effectively than anticipated, Goldman Sachs said. Twelve-month price target is $32.

Immunogen (IMGN) - Get Report was upgraded at UBS to neutral from sell. Bullish outlook on Kadcyla and royalty revenue providing lower-risk valuation support, UBS said. Twelve-month price target is $13.

[Read: 4 Rising High-Yield Dividend Stocks to Buy on Your Road to Wealth]

Points International (PCOM) - Get Report was downgraded to hold at TheStreet Ratings.

Phoenix Companies (PNX) was upgraded to hold at TheStreet Ratings.

Springleaf (LEAF) - Get Report was downgraded at Sterne Agee to neutral. Twelve-month price target is $28. Estimates were also cut, because of weakness in two units, Sterne Agee said.

Sprouts (SFM) - Get Report was upgraded at Credit Suisse to outperform from neutral. Twelve-month price target is $34. Pullback provides an opportunity, Credit Suisse said. Twelve-month price target is $34.

Triumph (TGI) - Get Report was upgraded at Credit Suisse to outperform from neutral. Company offers growth at a reasonable price, Credit Suisse said. Twelve-month price target is $88.

[Read: Monthly Beer Mailbag: A Gordon Biersch Birthday, SweetWater Turns Pils Pusher]

Theravance (THRX) was downgraded at Robert Baird to hold from buy. Valuation call, following the recent split, Robert Baird said.

Editor's note: To see analysts' stock comments and changes to price targets and earnings estimates, go to "Street Notes" which is available only to Real Money subscribers. To find out how to become a subscriber, please click here.

Follow TheStreet on Twitter and become a fan on Facebook.

Kass: Turn, Turn, Turn
Why Amazon Loves Local, and Why It Absolutely Shouldn't

This article was written by a staff member of TheStreet.